These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21565232)

  • 1. A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect?
    de Boer AH; Chan HK; Price R
    Adv Drug Deliv Rev; 2012 Mar; 64(3):257-74. PubMed ID: 21565232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces.
    Zhou QT; Morton DA
    Adv Drug Deliv Rev; 2012 Mar; 64(3):275-84. PubMed ID: 21782866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactose characteristics and the generation of the aerosol.
    Pilcer G; Wauthoz N; Amighi K
    Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of carrier surface treatment on drug particle detachment from crystalline carriers in adhesive mixtures for inhalation.
    Dickhoff BH; de Boer AH; Lambregts D; Frijlink HW
    Int J Pharm; 2006 Dec; 327(1-2):17-25. PubMed ID: 16920287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO; Molokhia AM; Elsayed MM
    Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physico-chemical aspects of lactose for inhalation.
    Kou X; Chan LW; Steckel H; Heng PW
    Adv Drug Deliv Rev; 2012 Mar; 64(3):220-32. PubMed ID: 22123598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proposed definition of the 'activity' of surface sites on lactose carriers for dry powder inhalation.
    Grasmeijer F; Frijlink HW; de Boer AH
    Eur J Pharm Sci; 2014 Jun; 56():102-4. PubMed ID: 24613490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of carrier particle shape on dry powder inhaler performance.
    Kaialy W; Alhalaweh A; Velaga SP; Nokhodchi A
    Int J Pharm; 2011 Dec; 421(1):12-23. PubMed ID: 21945739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance.
    Jones MD; Santo JG; Yakub B; Dennison M; Master H; Buckton G
    Int J Pharm; 2010 May; 391(1-2):137-47. PubMed ID: 20211715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical evaluation of the relevant parameters for drug redispersion from adhesive mixtures during inhalation.
    de Boer AH; Dickhoff BH; Hagedoorn P; Gjaltema D; Goede J; Lambregts D; Frijlink HW
    Int J Pharm; 2005 Apr; 294(1-2):173-84. PubMed ID: 15814242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers.
    Jones MD; Young P; Traini D
    Adv Drug Deliv Rev; 2012 Mar; 64(3):285-93. PubMed ID: 22265843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for reduction of cohesive forces between carrier and drug in DPI formulation.
    Desai SS; Aher AA; Kadaskar PT
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1589-98. PubMed ID: 23050727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Rational Design Space for Optimizing Mixing Conditions for Formation of Adhesive Mixtures for Dry-Powder Inhaler Formulations.
    Sarkar S; Minatovicz B; Thalberg K; Chaudhuri B
    J Pharm Sci; 2017 Jan; 106(1):129-139. PubMed ID: 27546350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dry powders for oral inhalation free of lactose carrier particles.
    Healy AM; Amaro MI; Paluch KJ; Tajber L
    Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
    Donovan MJ; Smyth HD
    Int J Pharm; 2010 Dec; 402(1-2):1-9. PubMed ID: 20816928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capabilities and limitations of using powder rheology and permeability to predict dry powder inhaler performance.
    Cordts E; Steckel H
    Eur J Pharm Biopharm; 2012 Oct; 82(2):417-23. PubMed ID: 22902789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.